RxDoctor Payments Data

Samrath Sokhey, DO

Family Medicine · Arlington, TXNPI 1548221633

Payments from drug & device makers

$536in general payments, 2019–2025

Across 33 payments — averaging $16.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$129
  • GSK$71
  • Amgen$61
  • Johnson & Johnson$52
  • Lilly USA, LLC$49
  • Novartis$33
  • plus $141 from 8 others

What the payments were for

  • Food & beverage$52598%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$536 in reported general payments places this provider in the 50th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$56,382
Medicare patients
113
Services billed
1,044

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide108$119,627
OzempicSemaglutide112$106,921
LinzessLinaclotide22$30,645
XareltoRivaroxaban27$25,112
MounjaroTirzepatide18$23,251
JardianceEmpagliflozin13$21,280
JanuviaSitagliptin Phosphate13$20,701
MyrbetriqMirabegron16$17,753
EliquisApixaban19$17,443
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$17,378
FarxigaDapagliflozin Propanediol15$14,684
SymbicortBudesonide/Formoterol Fumarate26$5,628
Lantus SolostarInsulin Glargine,hum.Rec.Anlog39$5,388
Dexlansoprazole DrDexlansoprazole12$3,780
Levothyroxine Sodium244$2,731

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$49$142,878126 claims
Novo NordiskOzempic$129$106,921112 claims
AbbVieLinzess$19$30,64522 claims
Johnson & JohnsonXarelto$52$25,11227 claims
Boehringer IngelheimJardiance$12$21,28013 claims
MerckJanuvia$22$20,70113 claims
Astellas Pharma US IncMyrbetriq$18$17,75316 claims
GSKTrelegy Ellipta$71$17,37828 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Arlington

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →